Use of a combination of the virus-neutralizing monoclonal antibodies casirivimab and imdevimab for mild to moderate COVID-19 in patients at high risk of progression: Results of the non-interventional observational study - PDF (Russian)
Copyright (c) 2023 Consilium Medicum
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.